Cover Image
Market Research Report

Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight

Published by PNS Pharma Product code 374507
Published Content info 35 Pages
Delivery time: 1-2 business days
Price
Back to Top
Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight
Published: October 17, 2016 Content info: 35 Pages
Description

"Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially available in India, Japan, Kenya, Czech Republic, Estonia, Germany, China, Slovakia, United Kingdom for the treatment of Type 1 & 2 diabetes mellitus. The patent on Lantus expired in 2014.

Lantus is the brand name for Insulin Glargine, a man made form of hormone generally produced in the human body, used in the treatment of diabetes mellitus in children and adults. The long lasting process of insulin works to lower down the levels of glucose (sugar) in blood. Lantus is also used to treat type 2 & type 1 diabetes in adults and children having more than 6 years of age. The drug usually starts working after several hours of injection and keeps performing for 18-26 hours or more without any pronounced peak.

Lantus is a package consisting of a sterile solution of insulin glargine containing zinc, m-cresol, glycerol 85%, polysorbate and water for injection as inactive ingredients. Each milliliter of Lantus contains 100 Units (3.6378mg) of insulin glargine. The pH of Lantus is adjusted by addition of hydrochloric acid and sodium hydroxide. It has a pH value of approximately 4 making it completely soluble. It is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) acting as production organism. Chemical representation of insulin glargine present in Lantus is 21A-Gly-30Ba-L-Arg-3030b-L-Arg-human insulin and empirical formula as C267H404N72O78S6 and a molecular weight of 6063.

The key function of Lantus consisting insulin is to regulate blood sugar levels is performed by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production. Lantus consists of a substitution of glycine as asparagine at N21 combining with 2 additional arginines to the carboxy terminal of B chain. The arginine amino acids are responsible for shifting the isoelectric point to 5.4 to 6.7, making the molecule more soluble in acidic pH and less soluble in physiological pH. This shift allows a subcutaneous injection of a clear solution.

Lantus treatment demands for daily dosage as injection under the skin into the subcutaneous tissue and not intravenously or by using insulin pumps. The injection is to be taken once in day time followed by 1 injection each day at the same time. The dosage is adjusted according to individual's physical activity, severe conditions of illness and changes in food intake. It is injected into abdominal area, thigh and deltoid. The place to inject can be replaced within the region to reduce the risk of side effects.

Table of Contents

Table of Contents

1. Lantus (Insulin glargine) Clinical Insight

  • 1.1 Clinical Introduction
  • 1.2 Patent Analysis by Indication
  • 1.3 Phase of Development
  • 1.4 Brand Names by Country/Region

Lantus Biosimilars Clinical Insight by Company

2. Insulin Glargine (Insulin U300)

  • 2.1 Clinical Insight
  • 2.2 Development Timeline
  • 2.3 Patent Analysis
  • 2.4 Phase of Development

3. Insulin Glargine - HEC Pharm

  • 3.1 Clinical Insight
  • 3.2 Phase of Development

4. Insulin Glargine Biosimilar - Biocon/Mylan

  • 4.1 Clinical Insight
  • 4.2 Development Timeline
  • 4.3 Phase of Development

5. Insulin Glargine Biosimilar - Boehringer Ingelheim/Eli Lilly

  • 5.1 Clinical Insight
  • 5.2 Development Timeline
  • 5.3 Patent Analysis
  • 5.4 Phase of Development

6. Insulin Glargine Biosimilar - Gan & Lee Pharmaceuticals

  • 6.1 Clinical Insight
  • 6.2 Development Timeline
  • 6.3 Phase of Development

7. Insulin Glargine Biosimilar - GEROPHARM

  • 7.1 Clinical Insight
  • 7.2 Phase of Development

8. Insulin Glargine Biosimilar - Harvest Moon Pharmaceuticals

  • 8.1 Clinical Insight
  • 8.2 Phase of Development

9. Insulin Glargine Biosimilar - LG Life Sciences

  • 9.1 Clinical Insight
  • 9.2 Phase of Development

10. Insulin Glargine Biosimilar - Paras Biopharmaceuticals

  • 10.1 Clinical Insight
  • 10.2 Patent Analysis
  • 10.3 Phase of Development

11. Insulin Glargine Biosimilar - Samsung Bioepis/Merck & Co.

  • 11.1 Clinical Insight
  • 11.2 Development Timeline
  • 11.3 Patent Analysis
  • 11.4 Phase of Development

12. Insulin Glargine Biosimilar - Wockhardt

  • 12.1 Clinical Insight
  • 12.2 Development Timeline
  • 12.3 Phase of Development

13. Recombinant Insulin Glargine Biosimilar - Biogenomics

  • 13.1 Clinical Insight
  • 13.2 Phase of Development

List of Tables

  • Table 2-1: Insulin U300 Insulin Glargine by Indicaion & Phase
  • Table 3-1: HEC Pharm Insulin Glargine by Indication & Phase
  • Table 4-1: Biocon/Mylan Insulin Glargine Biosimilar by Indication & Phase
  • Table 5-1: Boehringer Ingelheim/Eli Lilly Insulin Glargine Biosimilar by Indication & Phase
  • Table 6-1: Gan & Lee Pharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
  • Table 7-1: GEROPHARM Insulin Glargine Biosimilar by Indication & Phase
  • Table 8-1: Harvest Moon Pharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
  • Table 9-1: LG Life Sciences Insulin Glargine Biosimilar by Indication & Phase
  • Table 10-1: Paras Biopharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
  • Table 11-1: Samsung Bioepis/Merck & Co. Insulin Glargine Biosimilar by Indication & Phase
  • Table 12-1: Wockhardt Insulin Glargine Biosimilar by Indication & Phase
  • Table 13-1: Biogenomics Recombinant Insulin Glargine Biosimilar by Indication & Phase
Back to Top